The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Land-based Broodstock Facility Reaches Milestone

30 Oct 2017 07:00

RNS Number : 9021U
Benchmark Holdings PLC
30 October 2017
 

Benchmark Holdings plc("Benchmark" or the "Company")

 

Construction of land-based salmon broodstock facility reaches significant milestone

 

Benchmark today announces that its new land-based salmon broodstock facility in Norway is now ready to house its first batch of broodstock. The 10,000 square-meter facility will receive delivery of the first stock in November from Salten, the joint venture partner of Benchmark's subsidiary SalmoBreed, who have been growing SalmoBreed's genetic material. Salmon eggs from this stock will be produced early Autumn 2018 and first test batch sales are expected two months later.

 

The new facility will deliver eggs throughout the year for the entire production cycle and will be the first of its kind to do so in Norway. Smolt (young salmon) from SalmoBreed's breeding station in Lønningdal will also be delivered in November. This new site, which is based on Benchmark's Icelandic model, is fully-biosecure and has the capacity to produce over 150 million ova per year.

 

The build of the facility is on schedule and is expected to reach full capacity by Autumn 2019.

 

Malcolm Pye, Benchmark CEO, commented:

"SalmoBreed Salten will be the world's most advanced facility. This additional capacity will allow us to take up our production to meet the increasing demand for disease free, year-round salmon ova and support the strong growth of the Norwegian salmon industry.

 

"Norway is a leading player in salmon and there is a continuous drive towards improvements in production efficiency traits, disease resistance and product quality . Benchmark are well-placed to address this through our robust breeding programmes that are proven to tackle some of the industry's biggest challenges."

 

 

-ENDS-

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

Rachel Aninakwah, Communications

Numis

Tel: 020 7260 1000

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

Tavistock

Tel: 020 7920 3150

Sophie Praill / Simon Hudson

 

Notes to Editors:

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

 

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology, Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

 

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 September 2017, Benchmark employed 952 people. 

 

For further information on Benchmark please visit www.benchmarkplc.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABIBDGXDDBGRC
Date   Source Headline
27th Nov 20187:00 amRNSSuccessful defence of patent infringement in Asia
7th Nov 20187:00 amRNSTrading Statement
31st Oct 20187:00 amRNSTotal Voting Rights
23rd Oct 20184:55 pmRNSHolding(s) in Company
22nd Oct 20185:52 pmRNSHolding(s) in Company
10th Oct 20182:53 pmRNSDIRECTOR DEALINGS
3rd Oct 20187:00 amRNSAcquisition and Issue of Equity
2nd Oct 20187:00 amRNSAppointment of Chief Scientific Officer
28th Sep 20187:00 amRNSTotal Voting Rights
21st Sep 20187:00 amRNSBlock listing Interim Review
12th Sep 20187:00 amRNSBlock Admission Application
10th Sep 20187:00 amRNSCommencement of salmon egg production in Salten
30th Aug 20187:00 amRNSTotal Voting Rights
30th Jul 20187:00 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.